HomeAI · summaries
Storia in 3 fonti
Emcure Pharma gets CDSCO nod to market Poviztra for fatty liver treatment
Emcure Pharmaceuticals announced its brand Poviztra is now available for fatty liver treatment. This follows regulatory approval for treating metabolic dysfunction-associated steatohepatitis in adults. Poviztra contains innovator semaglutide manufactured in Europe by Novo Nordisk. The approval expands access to treatment for this progressive liver disease. This marks a significant milestone for patients with this serious condition.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
thehindu.com
India approves Novo Nordisk’s weight loss drug Wegovy for fatty liver disease
The Central Drugs Standard Control Organization (CDSCO) has approved Danish major Novo Nordisk’s weight loss drug Wegovy (semaglutide injection 2.4 mg) for a new indication —…
- ·
thehindubusinessline.com
Emcure's Poviztra gets CDSCO approval for fatty liver treatment
Emcure's semaglutide brand Poviztra has received CDSCO approval for treating MASH, expanding access to fatty liver treatment in India.
